Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: Subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study

Pharmacotherapy

Volumn 29, Issue 10, 2009, Pages 1157-1165

  Smith, Steven M ^a,c   Anderson, Shawn D ^d   Wen, Sheron ^a   Gong, Yan ^a,b   Turner, Stephen T ^e   Cooper DeHoff, Rhonda M ^a,b   Schwartz, Gary L ^e   Bailey, Kent ^e   Chapman, Arlene ^f   Hall, Karen L ^c   Feng, Hua ^a   Boerwinkle, Eric ^g   Johnson, Julie A ^a,b   Gums, John G ^a,b,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e MAYO CLINIC   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

Hydrochlorothiazide; Hyperglycemia; Hypokalemia; Thiazide diuretics; Thiazide induced hyperglycemia

Indexed keywords

GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; POTASSIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHARMACOGENOMICS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN; MALE; MIDDLE AGED; POTASSIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 70349668312     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1157     Document Type: Article

References (29)

1. ▶1. Ezzati M, Lopez AD, Rogers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360 (Pubitemid 35341298)
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223 (Pubitemid 40138015)
3. ▶3. Ma J, Stafford RS. Screening, treatment, and control of hypertension in U.S. private physician offices, 2003-2004. Hypertension 2008;51:1275-1281
4. ▶4. Writing Group Members for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update [online exclusive article]. Circulation 2008;117:e25-146.
5. ▶5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
6. ▶6. Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-2997
7. ▶7. The SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-3264
8. ▶8. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544
9. ▶9. Carter BL, Enhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008;52:30-36
10. Langford HG, Cutter G, Oberman A, Kansal P, Russell G. The effect of thiazide therapy on glucose, insulin and cholesterol metabolism and of glucose on potassium: results of a cross-sectional study in patients from the hypertension detection and followup program. J Hum Hypertens 1990;4:491-500. (Pubitemid 20375042)
11. ▶11. Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008;52:1022-1029
12. ▶12. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-224
13. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension 1992;19(suppl II):II26-9.
14. McFarland KF, Carr AA. Changes in the fasting blood sugar after hydrochlorothiazide and potassium supplementation. J Clin Pharmacol 1977;17:13-17.
15. Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation 1972;45:991-1004.
16. ▶16. Eriksson JW, Jansson P, Carlberg B, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension 2008;52:1030-1037
17. Wilkins RW. New drugs for the treatment of hypertension. Ann Intern Med 1959;50:1-10.
18. Rapoport MI. Thiazide-induced glucose intolerance treated with potassium. Arch Intern Med 1964;113:405-408
19. Goldner MG, Zarowitz H, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med 1960;262:403-405
20. Sagild U, Andersen V, Andreasen PB. Glucose tolerance and insulin responsiveness in experimental potassium depletion. Acta Medica Scandinavica 1961;169:243-251
21. ▶21. Carter BL. Preventing thiazide-induced hyperglycemia: opportunities for clinical pharmacists. Pharmacotherapy 2008;28:1425-1428
22. ▶22. Mariosa LS, Ribeiro-Filho FF, Batista MC, et al. Abdominal obesity is associated with potassium depletion and changes in glucose homeostasis during diuretic therapy. J Clin Hypertens 2008;10:443-449
23. ▶23. Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009;157:442-449
24. ▶24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): final report. Circulation 2002;106:3143-3421
26. ▶26. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9.
27. ▶27. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358 (Pubitemid 43740274)
28. ▶28. Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone vs spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrin Metab 2009;94:1361-1366
29. ▶29. Angarwal R. Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. Hypertension 2008;52:1012-1013